Phase 2 UNITY-NHL Study Regarding Umbralisib
15 apr 2021 ·
2 min. 31 sec.
![Phase 2 UNITY-NHL Study Regarding Umbralisib](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/original/a4ba234317a2c2c76532864ba9553574.jpg)
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
Descrizione
Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.
Informazioni
Autore | Peter Ciszewski, CheckRare |
Sito | - |
Tag |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company